Navigation Links
Neptune Technologies decided not to re-price options
Date:9/12/2008

LAVAL, QC, Sept. 12 /PRNewswire-FirstCall/ - The Board of Directors of Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) decided not to re-price any options including the previously announced 850,000 options owned by officers and directors.

About Neptune Technologies

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is sponsoring clinical research to demonstrate the therapeutic benefits in various medical indications. The Company patents its intellectual property, protects its industrial secrets and innovations and continuously expands its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnerships with worldwide leaders in the nutraceutical industries. Neptune has signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
2. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
3. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
4. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
5. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
6. Neptune Technologies expands into medicinal markets in Asia Pacific
7. Neptune Technologies receives GRAS notification in the United States
8. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
9. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
10. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
11. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... COLORADO SPRINGS, CO , March 29, 2017 /PRNewswire/ - Last year,s ... who support kratom are not the only efforts active to generate ... that substitute opiate based pharmaceutical drugs in the healthcare market place. ... Earlier this ... U.S. based developer and distributor of pharmaceutical and nutritional products, announced ...
(Date:3/29/2017)... ... , ... ComplianceOnline, the leading governance, risk and compliance advisory network with over ... 2017 venue and speaker lineup. The Summit will take place on June 8 and ... Parker House Hotel, which is located at 60 School Street, Boston, MA will be ...
(Date:3/29/2017)... CA (PRWEB) , ... March 29, 2017 , ... ... cutting edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy ... Today the company announced that its new round of awards are being ...
(Date:3/29/2017)... DIEGO and NEWARK, Del. ... , a privately-held regenerative medicine company, and W. ... materials science company, today announced a collaborative research agreement ... novel implantable cell therapy delivery device technologies that provide ... than a decade, ViaCyte has been developing innovative stem ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that ... uncover insights to support its reporting, help direct future campaigns, and ... youth charity will be using Brandwatch Analytics social listening and analytics ... of the topics and issues that are a priority for its ... "Until recently ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):